Inflammatory molecules: A target for treatment of systemic autoimmune diseases

A. Tincani, L. Andreoli, C. Bazzani, D. Bosiso, S. Sozzani

Research output: Contribution to journalArticlepeer-review


Inflammation is a process to protect the host against infection and danger signals. However, many pathologic conditions, including autoimmune diseases, are sustained by perpetual activation of the inflammatory process. In the past few years our knowledge about the molecular basis of inflammation have been uncovered and now much is known about the primary role of pro-inflammatory cytokines such as IL-1 and TNF. In the early '90s, anti-cytokine therapies started and confirmed the primary role of TNF in autoimmune diseases, such as rheumatoid arthritis, Crohn's Disease and psoriasis. Increasing understanding of the role of inflammatory mediators in inflammation and diseases is opening new avenues for the treatment of inflammatory-based diseases through selective targeting of cytokines and lipid mediators.

Original languageEnglish
Pages (from-to)1-7
Number of pages7
JournalAutoimmunity Reviews
Issue number1
Publication statusPublished - Nov 2007


  • Biological therapies
  • Chemokines
  • Inflammation
  • Rheumatoid Arthritis
  • Systemic Lupus Erythematosus

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy


Dive into the research topics of 'Inflammatory molecules: A target for treatment of systemic autoimmune diseases'. Together they form a unique fingerprint.

Cite this